Quantitative Analysis of Intramucosal Mast Cells in Irritable Bowel Syndrome
- 8 July 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 55 (3) , 244-249
Abstract
Goal: We aimed to study the density of intramucosal mast cells in histologically normal colonic mucosa biopsied from patients with a clinical diagnosis of irritable bowel syndrome (IBS). Background: Mast cell activation has been thought to implicate in the pathogenesis of inflammatory bowel disease (IBD). Whether it serves a role in the pathogenesis of IBS remains controversial. Study: A total of 127 colonoscopic mucosal biopsies were immunohistochemically stained, including 51 IBS, 66 IBD, and 10 normal control samples. Intact mast cells were quantified in 3 high power fields (HPF) in areas showing the highest density. Results: CD117 was sensitive in detecting mast cells in colonic mucosa. The mast cell counts in all biopsies ranged from 2 to 60 per HPF (mean=17.5±7.2). The density of intramucosal mast cells were similar among IBS, IBD and normal control groups (P=0.6733). IBD in remission versus IBS (17.1±8.0 vs. 18.1±7.0; P=0.4804), Crohn disease versus ulcerative colitis (17.1±10.4 vs. 17.2±5.2; P=0.9463), IBS with diarrhea versus without diarrhea (19.5±6.3 vs. 16.8±6.9; P=0.1404). Forty biopsies (31.5%) showing ≥20 mast cells per HPF appeared to equally distribute among various disease groups (P=0.7283). Conclusions: There is no significant difference in the number of intramucosal mast cells between IBS and IBD that show normal colonic biopsies. In IBS patients, the number of intramucosal mast cell does not correlate with symptoms. The mast cell count (≥20/HPF) is not a reliable criterion for the diagnosis of IBS or for the distinction between patients with IBS and those with IBD in remission.Keywords
This publication has 42 references indexed in Scilit:
- The Immune System in Irritable Bowel SyndromeJournal of Neurogastroenterology and Motility, 2011
- Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: Role of corticotropin-releasing factor receptorsBrain, Behavior, and Immunity, 2010
- Postinfectious Irritable Bowel SyndromeGastroenterology, 2009
- Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal painGut, 2008
- Reduced immunostaining for c‐kit receptors in mucosal mast cells in inflammatory bowel diseaseJournal of Gastroenterology and Hepatology, 2007
- Role for protease activity in visceral pain in irritable bowel syndromeJournal of Clinical Investigation, 2007
- Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunumGut, 2007
- Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel diseaseHistopathology, 1996
- Terminal ileal mucosal mast cells in irritable bowel syndromeDigestive Diseases and Sciences, 1993
- Significance of eosinophil and mast cell counts in rectal mucosa in ulcerative colitisDigestive Diseases and Sciences, 1987